Cyclica and ImmuneMed Form Agreement to Collectively Develop Pancreatic Cancer Therapeutics
Toronto, Canada and Seoul, Republic of Korea — Cyclica Inc. (“Cyclica”), the partner of choice for data driven drug discovery, and ImmuneMed Inc. (“ImmuneMed”), a developer of treatments for viral and inflammatory diseases, announce a collaboration to discover and develop small molecule therapeutics for pancreatic cancer. Pursuant to the collaboration, Cyclica will screen, identify and […]
Cyclica and the Structural Genomics Consortium co-crystallize DCAF1, a key component in proteasomal degradation, with a novel ligand to support targeted therapeutics discovery
Toronto, Canada — Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all. As part of the initiative, the […]
How this company is using data-driven drug discovery to fight disease (source: The Globe and Mail)
This post was adapted from its original source and can be viewed here. It can take, on average, more than a decade and about $1-billion for a new pharmaceutical drug to make its way from the lab to the prescription pad. Just five in 5,000 drugs that enter preclinical testing advance to human clinical trials. […]
Cyclica named one of CIX ‘s 2021 Top 10 Growth Inductees
This post was adapted from its original source and can be viewed here. The selected companies represent a diverse range of technology companies spanning software, AI, medtech, fintech, big data, security, SaaS and cleantech sectors. These game-changing, on-the-rise companies were chosen by the CIX 2021 Selection Committee of 100+ global technology investors. Read the full article at CIX →
Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development
21 September, 2021, Toronto, Canada and Shanghai, China — Cyclica, the partner of choice for data-driven drug discovery, and IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics with synthetic lethality approach, announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug […]
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cure Collaboration creates opportunities to identify, validate, and progress new medicines for CDD more rapidly and at a lower cost by derisking biological target and drug candidate selection CHERRY HILL, NJ and TORONTO, CANADA – August 19, 2021 – […]
A genetic inheritance from Neanderthals holds therapeutic promise for a 21st century pandemic
Montreal, July 8, 2021 – Earlier this year, a team of researchers with the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) and the Biobanque Quebec COVID-19 discovered that people who had elevated levels of the protein OAS1 experienced less severe illness and lower rates of mortality when infected with COVID-19. In a […]
PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery
OXFORD, England & TORONTO, May 17, 2021 — PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an […]
New approaches to AI, cell biology may have uncovered a novel drug target for COVID-19: Humans themselves
This post was adapted from its original source on Fierce Biotech and can be viewed here. By combining artificial intelligence and an extensive atlas of protein biology, Cyclica is taking new approaches to searching for old drugs that could fight COVID-19—and, now, it’s helped find what could become a first-in-class candidate. While other drug and […]
Cyclica teams with academics to investigate COVID-19 treatment
This post was adapted from its original source on Outsourcing Pharma and can be viewed here. The drug-discovery firm has partnered with several academic institutions to explore a Novartis lung-cancer treatment’s potential in treating COVID-19. Read the full article on Outsourcing Pharma →